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treatment with zidovudine in patients with HIV 
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Zidovudine (3' -azido-2' ,3' - dideoxythymidinc) 
is a drug with provcd antihuman immuno-
deficicncy virus (HIV) reverse traßscriptase 
activity. It has bcen clearly demonstrated that 
thc bcnefits of zidovudinc outwcigb the risks of 
its usc. H Different adversc effeets have bcen 
reponed for zidovudine, including anacmia, 
neutropenia. nausea, vomiting, myalgias, abnor-
malities of livcr funetion, bluish nail pigmenta-
tion, headachcs, myositis, and trichiasis." 
Colom vision deficits have bcen reponed for 
patients with AIDS or HIV disease," and it has 
been shown that this defect is most prominent 
for tritan vision. ' The patbogencsis of eolour 
vision defieits in patients with HIV disease 
remains unclear. We wish to repon the occur-
renee of a temporary decrease in tritan colour 
contrast sensitivity in two patients with HIV 
disease starting or restarting treaunent with 
zidovudine. 
Casereports 
OASE 1 
A 31-year-old patient was referred to the 
university eye hospital for routine examination 
after diagnosis of HIV infection and Iympha-
denopathy syndrome. Tbe patient had attended 
the medical outpatient clink because of a 
1 month history of fever aeeompanicd by swcU-
ing of lymph nodes. He tested HIV positive for 
the first time during this diagnostic examination 
whieh was 2 wecks before lhc first ophthalmie 
examination. Visual acuity was 20120 in both 
eyes with correction. Biomicroscopic examina-
tion revealed normal findings except for a 
discrete sludging of the blood column in the 
conjunctival vessels. On indirect ophthalmo-
scopy five cotton wool spots were seen in the 
right eye, and one in the left eye. Colour contrast 
scnsitivity was tested using a high sensitivity 
computer graphlcs system devcloped by Ardcn 
et al.'o Tbe thresholds for the three colour 3XCS 
were within normal limits: tritan right eye (RE) 
4·7, and left eye (LE) 4·2; deutan RE 3·3, and 
LE 3·2; protan RE 3·0, and LE 3·1. Tbe age 
corrected normal mucs 3ft (mean (2 SE»): tritan 
3·9 (2·2); deutan 4·3 (2·2); and protan 4·0 (1·9). 
Tbe absolute CD4+ Iymphocytc count was 
219 x 10'11, and treatment with zidovudine (500 
mg per day) was staned. Thls was the only drug 
administered to the patient. Seven days after 
initiation of treatment with zidovudine the 
patient attended hospital with a 3 day experienee 
of sligbtly blurred vision in both eycs. Ophthal-
mie examination, and deutan and protan colour 
vision were unchanged, but tritan vision was 
impaired: tritan RE 7·4,and LE 7·S. Zidovudine 
treatment was continued. One weck later the 
subjective symptoms disappearcd. Tritan thres-
holds were REj·4, and LE 4·6. On subS;CQuent 
foUow ups tritan vision improved to baseline 
levels, and was in a range betwecn 3·7 and 4· 3 in 
both eyes. 
OASE 2 
Tbe second patient was a 26-year-old woman 
with a 9 month history of AIDS after one episode 
of Pnewnocystis carinii pneumonia. She was 
referred to the university eye hospital for 
ophthalmie examination because of diplopia. 
Treatment with zidovudine bad been dis-
continued 2 months earlier because of neutm-
penia, but the patient was still on Pneumocystis 
cannii prophylaxis with trimethoprim and 
sulphamethoxazole. Tbe absolute CD4+ 
Iymphocyte count was 70x 10"11. Visua1 acuity 
was 20120 in both eyes with correction. 
Ophthalmie examination revealed a sixth nerve 
palsy of the right eye. Otherwise ophthalmie 
examination was nonnal and colouf contrast 
sensitivity thresholds were within nonnallimits: 
tritan RE 3·g, and LE 3·9; deutan RE 3·6, and 
LE 3·6; protan RE 3·7. and LE 3·7. 
Cranial magnetic resonance imaging showed a 
lesion in the area of the right pons and a second 
lesion in the left anterior part of the corpus 
eallosum, both with surrounding oedema. Clear 
ring-like enhancement was seen after application 
of Gd-DTPA. The location of the lesion in the 
pons was in accordance with compressive 
damage to the intracerebral path of the sixth 
nervc. Thc diagnosis of cerebral toxoplasmosis 
was assumed, and treatment with pyrimetha-
mine (50 mg per day), c1indamycin (2400 mg per 
day), and folinic acid (15 mg per day) was 
started. Ten days later diplopia disappeared. 
Treatment with zidovudine (500 mg per day) was 
re-establisbed 2 months later. Tritan COIOUf 
contrast sensitivity increased to RE 6·4, and LE 
6·5 measured 3 days after the reJ.D.luauon of 
treatment with zidovudine, but otherwise 
ophthalmie findings were normal, especially the 
values for deutan and protan vision. Two weeks 
later tritan eolour contrast sensitivity was 
RE 3'5, and LE 3·8 and other findings were 
unehanged. 
Comment 
Alterations of eolour vision bave been reported 
for numerous drugs."" Aequired alterations 
of tritan vision are usually related to retinal 
damage." Tberefore, the dyschromatopsia in the 
(Wo reported cases is expected to be related to 
retinal damage. 
Recently, retinal damage bas been reported 
for ehildren treated with 2' ,3' - dideoxyinosine." 
The authors used electropbysiological methods 
to measure retinal funetion, but no testS for 
colour vision were perfonned. They suggest that 
2' ,3'-dideoxyinosine, whieh is also a dideoxy-
nucleoside like zidovudine, causes a diffuse 
dysfunction of the retinal pigment epithelium. 
The pathogenesis of eolour vision deficits in 
patients with symptomatic HIV infection or 
AIDS remains unclear. It was proposed that the 
HIV-related retinal mieroangiopathic syndrome 
plays an importaDt role in the pathogenesis of 
those colour vision deficits. Our observations 
suggest that a temporary shift in tritan colour 
vision is an adverse effect at the beginning of 
treatment with zidovudine. Tbis shift in tritan 
vision might be due to a temporary interference 
of zidovudine with the production of visual 
pigment, or a temporary alteration of the pig-
ment epithelium. Nevertheless, other factors 
may underly the changes. It cannot be ruled out 
that long tenn application of zidovudine might 
contribute to the development of colour vision 
deficits described for patients with HIV disease. 
Health care professionals involved in the treat-
ment of patients with HlV disease sbould be 
aware of any abnormal deug or disease related 
effects. 
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